On August 6, 2019 Idera Pharmaceuticals, Inc. ("Idera") (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease indications, reported that second quarter results for 2019 are expected to be released on Thursday, August 8, 2019 before the opening of the U.S. financial markets (Press release, Idera Pharmaceuticals, AUG 6, 2019, View Source [SID1234538317]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will host a conference call and live audio webcast at 10:00 A.M. eastern time on the same day. During the conference call, Idera management will also provide a corporate update along with a question and answer session.

To participate in the conference call, please dial (844) 882-7837 (domestic) and (574) 990-9824 (international). The webcast can be accessed live or in archived form in the "Investors" section of the company’s website at www.iderapharma.com. Archived versions will also be available on the Company’s website after the event for 90 days.